NO314568B1 - Kombinasjon mot HIV-infeksjon ved anvendelse av HIV-protease- inhibitoren indinavir og reverstranskriptaseinhibitoren 3TC sammen med AZT - Google Patents

Kombinasjon mot HIV-infeksjon ved anvendelse av HIV-protease- inhibitoren indinavir og reverstranskriptaseinhibitoren 3TC sammen med AZT Download PDF

Info

Publication number: NO314568B1
Authority: NO; Norway
Prior art keywords: hiv; reverse transcriptase; azt; pharmaceutically acceptable; combination
Prior art date: 1995-02-01

Application number

NO19973533A

Other languages

English (en)

Norwegian (no)

Other versions

NO973533D0 (no

NO973533L (no

Inventor

Jeffrey A Chodakewitz

Emilio A Emini

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-01

Filing date

1997-07-31

Publication date

2003-04-14

1997-07-31 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1997-07-31 Publication of NO973533D0 publication Critical patent/NO973533D0/no

1997-10-01 Publication of NO973533L publication Critical patent/NO973533L/no

2003-04-14 Publication of NO314568B1 publication Critical patent/NO314568B1/no

Links

239000003419 rna directed dna polymerase inhibitor Substances 0.000 title claims description 7
208000031886 HIV Infections Diseases 0.000 title claims description 6
208000037357 HIV infectious disease Diseases 0.000 title claims description 6
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims description 6
229940122440 HIV protease inhibitor Drugs 0.000 title description 3
239000004030 hiv protease inhibitor Substances 0.000 title description 3
229960001936 indinavir Drugs 0.000 title 1
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 21
208000030507 AIDS Diseases 0.000 claims description 17
108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 9
239000002777 nucleoside Substances 0.000 claims description 8
150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
241000725303 Human immunodeficiency virus Species 0.000 description 15
238000000034 method Methods 0.000 description 14
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 10
229960002555 zidovudine Drugs 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
-1 digluconate Chemical compound 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108010010369 HIV Protease Proteins 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
230000032050 esterification Effects 0.000 description 5
238000005886 esterification reaction Methods 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
206010001513 AIDS related complex Diseases 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000010933 acylation Effects 0.000 description 3
238000005917 acylation reaction Methods 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000012024 dehydrating agents‎ Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002904 solvent Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000006000 trichloroethyl group Chemical group 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
238000007445 Chromatographic isolation Methods 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000012266 Needlestick injury Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000012190 activator Substances 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000004694 iodide salts Chemical class 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
238000006894 reductive elimination reaction Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19973533A 1995-02-01 1997-07-31 Kombinasjon mot HIV-infeksjon ved anvendelse av HIV-protease- inhibitoren indinavir og reverstranskriptaseinhibitoren 3TC sammen med AZT NO314568B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/382,113 US6689761B1 (en)	1995-02-01	1995-02-01	Combination therapy for HIV infection
PCT/US1996/001417 WO1996023509A1 (en)	1995-02-01	1996-01-29	Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc

Publications (3)

Publication Number	Publication Date
NO973533D0 NO973533D0 (no)	1997-07-31
NO973533L NO973533L (no)	1997-10-01
NO314568B1 true NO314568B1 (no)	2003-04-14

Family

ID=23507574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19973533A NO314568B1 (no)	1995-02-01	1997-07-31	Kombinasjon mot HIV-infeksjon ved anvendelse av HIV-protease- inhibitoren indinavir og reverstranskriptaseinhibitoren 3TC sammen med AZT

Country Status (37)

Country	Link
US (1)	US6689761B1 (da)
EP (1)	EP0806957B1 (da)
JP (1)	JPH10513186A (da)
KR (1)	KR19980701856A (da)
CN (1)	CN1160081C (da)
AR (1)	AR002957A1 (da)
AT (1)	ATE243519T1 (da)
AU (1)	AU711176B2 (da)
BR (1)	BR9607714A (da)
CA (1)	CA2211973A1 (da)
CO (1)	CO4700430A1 (da)
CZ (1)	CZ244497A3 (da)
DE (1)	DE69628819T2 (da)
DK (1)	DK0806957T3 (da)
DZ (1)	DZ1988A1 (da)
EA (1)	EA000437B1 (da)
EE (1)	EE03514B1 (da)
ES (1)	ES2200052T3 (da)
FI (1)	FI973184L (da)
HR (1)	HRP960045B1 (da)
HU (1)	HUP9800810A3 (da)
IL (1)	IL116925A (da)
IS (1)	IS1970B (da)
MX (1)	MX9705916A (da)
MY (1)	MY121604A (da)
NO (1)	NO314568B1 (da)
NZ (1)	NZ302153A (da)
PE (1)	PE38397A1 (da)
PL (1)	PL182742B1 (da)
PT (1)	PT806957E (da)
SA (1)	SA96160669B1 (da)
SK (1)	SK103797A3 (da)
TR (1)	TR199700735T1 (da)
TW (1)	TW442291B (da)
WO (1)	WO1996023509A1 (da)
YU (1)	YU49417B (da)
ZA (1)	ZA96722B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0942747A1 (en) *	1996-08-26	1999-09-22	Chiron Corporation	Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU6761198A (en) *	1998-03-17	1999-10-11	Julianna Lisziwiewicz	Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6875773B1 (en)	1998-05-29	2005-04-05	Ben M. Dunn	Combination therapy for treatment of FIV infection
CA2374198A1 (en) *	1998-05-29	1999-12-02	Maki Arai	Combination therapy for treatment of fiv infection
EP1980617A1 (en)	1998-12-31	2008-10-15	Novartis Vaccines and Diagnostics, Inc.	Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2452015C (en)	2001-07-05	2012-07-03	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2583195A1 (en) *	2004-11-19	2006-05-26	Boehringer Ingelheim International Gmbh	Method for treating hiv infection through co-administration of tipranavir and reverset
WO2007012177A1 (en) *	2005-07-27	2007-02-01	Emil Toma	Zalcitabine (ddc) boosted lamivudine (3tc) compositions for antiretroviral therapy
WO2018128993A1 (en) *	2017-01-04	2018-07-12	Oyagen, Inc.	Compounds, compositions, and methods for treating human immunodeficiency virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
US5254539A (en) *	1985-08-26	1993-10-19	U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health	Method of treating HIV with 2',3'-dideoxyinosine
US5028595A (en) *	1987-09-18	1991-07-02	Hoffmann-La Roche Inc.	Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
IL100502A (en)	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US5413999A (en) *	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
RU2139052C1 (ru)	1993-03-31	1999-10-10	Мерк Энд Ко., Инк.	Комбинация ингибитора вич-протеазы с другими антивирусными соединениями, фармацевтическая композиция на их основе и способ получения фармацевтической композиции
IL114208A0 (en)	1994-06-27	1995-10-31	Merck & Co Inc	Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors

1995
- 1995-02-01 US US08/382,113 patent/US6689761B1/en not_active Expired - Fee Related
1996
- 1996-01-26 IL IL11692596A patent/IL116925A/xx not_active IP Right Cessation
- 1996-01-29 AT AT96903770T patent/ATE243519T1/de not_active IP Right Cessation
- 1996-01-29 EE EE9700165A patent/EE03514B1/xx not_active IP Right Cessation
- 1996-01-29 HU HU9800810A patent/HUP9800810A3/hu unknown
- 1996-01-29 NZ NZ302153A patent/NZ302153A/xx unknown
- 1996-01-29 JP JP8523739A patent/JPH10513186A/ja not_active Withdrawn
- 1996-01-29 EP EP96903770A patent/EP0806957B1/en not_active Expired - Lifetime
- 1996-01-29 SK SK1037-97A patent/SK103797A3/sk unknown
- 1996-01-29 DK DK96903770T patent/DK0806957T3/da active
- 1996-01-29 EA EA199700150A patent/EA000437B1/ru not_active IP Right Cessation
- 1996-01-29 DE DE69628819T patent/DE69628819T2/de not_active Expired - Fee Related
- 1996-01-29 PT PT96903770T patent/PT806957E/pt unknown
- 1996-01-29 MX MX9705916A patent/MX9705916A/es not_active IP Right Cessation
- 1996-01-29 WO PCT/US1996/001417 patent/WO1996023509A1/en not_active Ceased
- 1996-01-29 CN CNB961929103A patent/CN1160081C/zh not_active Expired - Fee Related
- 1996-01-29 AU AU47748/96A patent/AU711176B2/en not_active Ceased
- 1996-01-29 CZ CZ972444A patent/CZ244497A3/cs unknown
- 1996-01-29 FI FI973184A patent/FI973184L/fi not_active Application Discontinuation
- 1996-01-29 ES ES96903770T patent/ES2200052T3/es not_active Expired - Lifetime
- 1996-01-29 TR TR97/00735T patent/TR199700735T1/xx unknown
- 1996-01-29 CA CA002211973A patent/CA2211973A1/en not_active Abandoned
- 1996-01-29 KR KR1019970705253A patent/KR19980701856A/ko not_active Ceased
- 1996-01-29 BR BR9607714A patent/BR9607714A/pt not_active Application Discontinuation
- 1996-01-30 HR HR960045A patent/HRP960045B1/xx not_active IP Right Cessation
- 1996-01-31 MY MYPI96000349A patent/MY121604A/en unknown
- 1996-01-31 PE PE1996000073A patent/PE38397A1/es not_active Application Discontinuation
- 1996-01-31 AR ARP960101221A patent/AR002957A1/es unknown
- 1996-01-31 DZ DZ960029A patent/DZ1988A1/fr active
- 1996-01-31 ZA ZA96722A patent/ZA96722B/xx unknown
- 1996-02-01 YU YU6396A patent/YU49417B/sh unknown
- 1996-02-01 CO CO96004316A patent/CO4700430A1/es unknown
- 1996-02-06 TW TW085101447A patent/TW442291B/zh not_active IP Right Cessation
- 1996-03-12 SA SA96160669A patent/SA96160669B1/ar unknown
1997
- 1997-07-29 IS IS4533A patent/IS1970B/is unknown
- 1997-07-31 NO NO19973533A patent/NO314568B1/no not_active IP Right Cessation
- 1997-09-29 PL PL96321660A patent/PL182742B1/pl unknown

Also Published As

Publication number	Publication date
CZ244497A3 (cs)	1998-01-14
PT806957E (pt)	2003-10-31
CN1160081C (zh)	2004-08-04
CA2211973A1 (en)	1996-08-08
CO4700430A1 (es)	1998-12-29
TR199700735T1 (xx)	1998-02-21
IL116925A0 (en)	1996-05-14
HUP9800810A3 (en)	2001-05-28
TW442291B (en)	2001-06-23
YU49417B (sh)	2006-01-16
EA199700150A1 (ru)	1997-12-30
MY121604A (en)	2006-02-28
IS4533A (is)	1997-07-29
PL321660A1 (en)	1997-12-22
AU711176B2 (en)	1999-10-07
IS1970B (is)	2004-12-15
KR19980701856A (ko)	1998-06-25
ZA96722B (en)	1996-08-26
PE38397A1 (es)	1997-10-09
DZ1988A1 (fr)	2002-07-20
EE03514B1 (et)	2001-10-15
FI973184A7 (fi)	1997-09-30
FI973184A0 (fi)	1997-07-31
BR9607714A (pt)	1998-01-13
NO973533D0 (no)	1997-07-31
PL182742B1 (pl)	2002-02-28
DK0806957T3 (da)	2003-09-29
NZ302153A (en)	1998-12-23
CN1179722A (zh)	1998-04-22
DE69628819T2 (de)	2004-05-13
AU4774896A (en)	1996-08-21
ES2200052T3 (es)	2004-03-01
HK1004659A1 (en)	1998-12-04
EP0806957A1 (en)	1997-11-19
EP0806957B1 (en)	2003-06-25
EE9700165A (et)	1998-02-16
HRP960045A2 (en)	1997-10-31
US6689761B1 (en)	2004-02-10
WO1996023509A1 (en)	1996-08-08
MX9705916A (es)	1997-10-31
SA96160669B1 (ar)	2006-07-30
ATE243519T1 (de)	2003-07-15
EA000437B1 (ru)	1999-08-26
HUP9800810A2 (hu)	1998-07-28
FI973184L (fi)	1997-09-30
IL116925A (en)	2000-07-26
JPH10513186A (ja)	1998-12-15
HRP960045B1 (en)	2004-06-30
NO973533L (no)	1997-10-01
SK103797A3 (en)	1998-02-04
YU6396A (sh)	1999-06-15
DE69628819D1 (de)	2003-07-31
AR002957A1 (es)	1998-05-27

Legal Events

Date	Code	Title	Description
2004-12-13	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP0806957B1 (en)	2003-06-25	Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc together with azt.
US6911460B2 (en)	2005-06-28	Antiviral agents and methods of treating viral infections
US6180634B1 (en)	2001-01-30	Combination therapy for the treatment of AIDS
AU2863895A (en)	1996-01-19	Combination therapy for hiv infection
EP1044000B1 (en)	2002-06-12	Combination therapy for the treatment of aids
AU698664B2 (en)	1998-11-05	HIV protease inhibitor combination
HK1004659B (en)	2003-10-10	Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
CZ20001752A3 (cs)	2000-10-11	Farmaceutické prostředky obsahující kombinaci pro léčbu AIDS
CN1155841A (zh)	1997-07-30	Hiv感染的联合治疗